Indaptus Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
INDP$2.90-7.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $1,591,142 | $1,879,900 |
| General and administrative | 2,352,097 | 2,575,266 |
| Total operating expenses | 3,943,239 | 4,455,166 |
| Loss from operations | (3,943,239) | (4,455,166) |
| Other income, net | 136,562 | 201,928 |
| Net loss | $(3,806,677) | $(4,253,238) |
| Net loss available to common stockholders per share of common stock, basic and diluted | $(0.45) | $(0.51) |
| Weighted average number of shares used in calculating net loss per share, basic and diluted | 8,442,364 | 8,401,047 |
| Net loss | $(3,806,677) | $(4,253,238) |
| Other comprehensive income: | ||
| Reclassification adjustment for interest earned on marketable securities included in net loss | - | (129,229) |
| Change in unrealized gain on marketable securities | - | 210,252 |
| Comprehensive loss | $(3,806,677) | $(4,172,215) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.